Highlights

Innovation for the oral treatment of mucosal cancers

Our mission

Develop a safe and efficient therapeutic platform based on oral monoclonal IgA antibodies

Our focus

ABC-101, a unique, orally-active IgA anti-CEA developped for the treatment of mucosal cancers
ABC-201, an IgA monoclonal antibody currently under development in Endometriosis

Our goals

IND for ABC-101 in 2026 and a clinical POC in several mucosal cancers in 2027
IND for ABC-201 in 2027 for the treatment of Endometriosis

The most deadly cancers
are mucosal

New cases/year

5-Y survival

Global incidence: new cases/year 5 years survival rate (Source IARC 2020)

IgA as a valuable alternative to IgG

Its polymeric and T-shape
gives IgA a higher avidity
for its target than IgG
IgA recruits neutrophils, ten
times more efficiently than
NK cells recruited by IgG
IgA glycosylations are less
critical for cell cytotoxicity
induction than for IgG

Its polymeric and T-shape gives
IgA a higher avidity
for its target than IgG
IgA recruits neutrophils, ten
times more efficiently than
NK cells recruited by IgG
IgA glycosylations are less
critical for cell cytotoxicity
induction than for IgG

IgA is a unique antibody suitable for Oral immunotherapy
as an alternative to exclusively IV/SC IgG administration

A unique technological platform

IgA is extremely difficult to sort from standard hybridoma techniques (1% IgA vs 40% IgM, 60% IgG) and has thus being up to now under estimated by Pharma at the benefit of IgG approaches.

Abcely has developped a unique platform for the Identification, Lead Optimisation, Manufacturing, Analysis and in vitro/vivo testing of slgA

ABC-101
The first slgA
anti-CEA drug

Secretory IgA (sIgA) is extremely resistant to enzymatic attacks and high pH variations (from acidic to basic)

Secretory IgA is actively absorbed without degradation by receptors expressed on M cells, mostly located in Peyer Patches in human ileum

Carcinoembryonic antigen (CEA), present at the apical membrane of cells in normal tissues, is one of the most widely used tumor marker for monitoring tumor recurrence after surgical resection and prognosis. CEA overexpression is associated to many types of cancers (up to 98% of colorectal cancers) IgA is the only relevant Ig to target CEA because IgG binds to the plasma CEA and does not reach the tumor efficiently

In vivo efficacy of ABC-101 in an advanced metastatic CRC model After 3 weeks of oral treatment, ABC-101 was well tolerated As a first-line monotherapy, ABC-101 signicantly reduced tumor size when given orally and showed a higher therapeutic benefit than the clinical IgG SOC (Erbitux®) given in IV In combination with Irinotecan, ABC-101 given orally showed a stronger therapeutic benefit on tumor growth than the IV Gold standard IgG, Erbitux®

In vivo efficacy
of ABC-101 in
an advanced
metastatic CRC

In vivo efficacy of ABC-101 in an advanced metastatic CRC model.

After 3 weeks of oral treatment, ABC-101 was well tolerated .
As a first-line monotherapy, ABC-101 signicantly reduces tumor size when given orally and shows a higher therapeutic benefit than the clinical SOC (Erbitux®) given IV.